{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:08:27Z","timestamp":1790885307776,"version":"4.1.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intravitreal delivery of adeno-associated virus (AAV) vectors offers a promising, minimally invasive strategy for retinal gene therapy, but remains limited by dose-dependent intraocular inflammation. Corticosteroid therapy, the current standard for managing gene therapy-associated uveitis (GTAU), can be ineffective or contraindicated, highlighting the need for alternative immunomodulatory approaches and deeper understanding of AAV-induced inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using porcine and mice models, we characterized immune responses triggered by AAV2.7m8 vector.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Consistent with previous data for this serotype, AAV-mediated transgene expression localized predominantly to retinal ganglion cells, although photoreceptor, bipolar, amacrine, horizontal, and glia cells were also transduced. Despite prophylactic methylprednisolone, AAV-treated animals developed GTAU, accompanied by increased MCP-1, IP-10, MIP-1\u03b1 and IL-6 levels in ocular humors, along with microglial activation and peripheral leukocyte infiltration. Transcriptomic analysis revealed upregulation of antiviral interferon responses across all retinal cell populations, together with complement and DNA damage pathways. Accordingly, functional assays confirmed complement C3a accumulation in ocular humors and presence of \u03b3H2AX\n                      <jats:sup>+<\/jats:sup>\n                      DNA damage foci in transduced retinas. Finally, a mechanistic study of intravitreal AAV delivery in mice using integrin-blocking antibodies revealed a role for peripheral leukocytes in mediating ocular inflammation in this species.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our work identified new markers of ocular inflammation and potential targets to modulate GTAU.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1799327","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:53:57Z","timestamp":1776837237000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Intravitreal AAV vector delivery induces integrin-dependent ocular inflammation, complement activation, and antiviral and DNA damage responses"],"prefix":"10.3389","volume":"17","author":[{"given":"Helena","family":"Costa-Verdera","sequence":"first","affiliation":[{"name":"Immunology, Spark Therapeutics","place":["Philadelphia, PA, United States"]},{"name":"Ocular Research, Spark Therapeutics","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Jamwal","sequence":"additional","affiliation":[{"name":"Immunology, Spark Therapeutics","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Fabyanic","sequence":"additional","affiliation":[{"name":"Genomics and Data Science, Spark Therapeutics","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Hippen","sequence":"additional","affiliation":[{"name":"Genomics and Data Science, Spark Therapeutics","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Salvatore","sequence":"additional","affiliation":[{"name":"Immunology, Spark Therapeutics","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Du","sequence":"additional","affiliation":[{"name":"Non-clinical Research Operations, Spark Therapeutics","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Majowicz","sequence":"additional","affiliation":[{"name":"Immunology, Spark Therapeutics","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Markusic","sequence":"additional","affiliation":[{"name":"Immunology, Spark Therapeutics","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon E.","family":"Chatterton","sequence":"additional","affiliation":[{"name":"Ocular Research, Spark Therapeutics","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Haurigot","sequence":"additional","affiliation":[{"name":"Ocular Research, Spark Therapeutics","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Kuranda","sequence":"additional","affiliation":[{"name":"Immunology, Spark Therapeutics","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus integration: An integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.10.1.34","article-title":"Long-term safety evaluation of continuous intraocular delivery of aflibercept by the intravitreal gene therapy candidate ADVM-022 in nonhuman primates","volume":"10","author":"Kiss","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.03.031","article-title":"Durability of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease: Phase 3 results at 3 and 4 years","volume":"128","author":"Maguire","year":"2021","journal-title":"Ophthalmology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2018.06.006","article-title":"Seeing the light after 25 years of retinal gene therapy","volume":"24","author":"Trapani","year":"2018","journal-title":"Trends Mol Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.608377","article-title":"Immune privilege: The microbiome and uveitis","volume":"11","author":"Molzer","year":"2020","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2002.0525","article-title":"A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus","volume":"5","author":"Anand","year":"2002","journal-title":"Mol Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"476964","DOI":"10.1016\/j.jneuroim.2019.05.005","article-title":"Anterior chamber associated immune deviation to cytosolic neural antigens avoids self-reactivity after optic nerve injury and polarizes the retinal environment to an anti-inflammatory profile","volume":"333","author":"Mart\u00ednez-Alcantar","year":"2019","journal-title":"J Neuroimmunology"},{"key":"B9","article-title":"Characterization of suppressor cells in anterior chamber-associated immune deviation (ACAID) induced by soluble antigen. Evidence of two functionally and phenotypically distinct T-suppressor cell populations","volume":"71","author":"Wilbanks","year":"1990","journal-title":"Immunology"},{"key":"B10","article-title":"Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential","volume":"14","author":"Li","year":"2008","journal-title":"Mol Vision"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-22494","article-title":"Humoral immune response after intravitreal but not after subretinal AAV8 in primates and patients","volume":"59","author":"Reichel","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: A long journey to successful gene transfer","volume":"28","author":"Costa Verdera","year":"2020","journal-title":"Mol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.08.018","article-title":"AAV8 can induce innate and adaptive immune response in the primate eye","volume":"25","author":"Reichel","year":"2017","journal-title":"Mol Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-019-0060-0","article-title":"Factors governing the transduction efficiency of adeno-associated virus in the retinal ganglion cells following intravitreal injection","volume":"26","author":"Cao","year":"2019","journal-title":"Gene Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.043","article-title":"Retinal tropism and transduction of adeno-associated virus varies by serotype and route of delivery (intravitreal, subretinal, or suprachoroidal) in rats","volume":"31","author":"Han","year":"2020","journal-title":"Hum Gene Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fddev.2023.1148795","article-title":"AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery","volume":"3","author":"Koponen","year":"2023","journal-title":"Front Drug Delivery"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6250","article-title":"Intravitreal injection of AAV2 transduces macaque inner retina","volume":"52","author":"Yin","year":"2011","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.12.012","article-title":"Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset","volume":"128","author":"Newman","year":"2021","journal-title":"Ophthalmology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1006\/mcne.2002.1168","article-title":"Intravitreal injection of adeno-associated viral vectors results in the transduction of different types of retinal neurons in neonatal and adult rats: A comparison with lentiviral vectors","volume":"21","author":"Harvey","year":"2002","journal-title":"Mol Cell Neurosci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.02-1332","article-title":"Gene therapy with brain-derived neurotrophic factor as a protection: Retinal ganglion cells in a rat glaucoma model","volume":"44","author":"Martin","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.visres.2024.108519","article-title":"Intravitreal AAV2 gene delivery to feline retinal ganglion cells","volume":"226","author":"Oikawa","year":"2025","journal-title":"Vision Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.visres.2023.108196","article-title":"Adeno-associated virus mediated gene therapy for neuroprotection of retinal ganglion cells in glaucoma","volume":"206","author":"Starr","year":"2023","journal-title":"Vision Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.159","article-title":"Update on viral gene therapy clinical trials for retinal diseases","volume":"33","author":"Cheng","year":"2022","journal-title":"Hum Gene Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.12.4.20","article-title":"Intravitreal administration of AAV2-SIRT1 reverses diabetic retinopathy in a mouse model of type 2 diabetes","volume":"12","author":"Adu-Agyeiwaah","year":"2023","journal-title":"Transl Vis Sci Technol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"189ra176","DOI":"10.1126\/scitranslmed.3005708","article-title":"In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci Transl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2016.111","article-title":"Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the non-human primate retina","volume":"28","author":"Ramachandran","year":"2017","journal-title":"Hum Gene Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102394","article-title":"Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): A prospective, two-year, multicentre phase 1 study","volume":"67","author":"Khanani","year":"2024","journal-title":"eClinicalMedicine"},{"key":"B28","first-page":"5312","article-title":"Meta-analysis of gene therapy associated uveitis (GTAU)","volume":"65","author":"Buckley","year":"2024","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2025.101354","article-title":"Gene therapy-associated uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy","volume":"106","author":"Purdy","year":"2025","journal-title":"Prog Retinal Eye Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd3438","article-title":"Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses","volume":"13","author":"Chan","year":"2021","journal-title":"Sci Transl Med"},{"key":"B31","unstructured":"Adverum provides update on ADVM-022 and the INFINITY trial in patients with diabetic macular edema. News release\n          \n          \n          \n          2021"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.01.028","article-title":"Characterization of the ocular inflammatory response to AAV reveals divergence by sex and age","volume":"33","author":"Clare","year":"2025","journal-title":"Mol Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.62.2.41","article-title":"Characterization of gene therapy associated uveitis following intravitreal adeno-associated virus injection in mice","volume":"62","author":"Tummala","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.222","article-title":"The degree of adeno-associated virus-induced retinal inflammation varies based on serotype and route of delivery: Intravitreal, subretinal, or suprachoroidal","volume":"34","author":"Wiley","year":"2023","journal-title":"Hum Gene Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041296","article-title":"Pig models in retinal research and retinal disease","volume":"14","author":"McCall","year":"2024","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"16049","DOI":"10.1038\/mtm.2016.49","article-title":"A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome","volume":"3","author":"Ronzitti","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2009.157","article-title":"High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency","volume":"17","author":"Ayuso","year":"2010","journal-title":"Gene Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0108","article-title":"The SPOTS system: An ocular scoring system optimized for use in modern preclinical drug development and toxicology","volume":"33","author":"Eaton","year":"2017","journal-title":"J Ocul Pharmacol Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: A case series","volume":"231","author":"Chand","year":"2021","journal-title":"J Pediatr"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1038\/s41467-025-58778-3","article-title":"AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain","volume":"16","author":"Costa-Verdera","year":"2025","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/med.10001","article-title":"Inhibition of LFA-1\/ICAM-1 and VLA-4\/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases","volume":"22","author":"Yusuf-Makagiansar","year":"2002","journal-title":"Med Res Rev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2014.04.009","article-title":"Inhibition of very late antigen-4 and leukocyte function-associated antigen-1 in experimental autoimmune uveoretinitis","volume":"153","author":"Ishida","year":"2014","journal-title":"Clin Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.340408","article-title":"Regenerative capacity of M\u00fcller cells and their modulation as a tool to treat retinal degenerations","volume":"18","author":"Conedera","year":"2023","journal-title":"Neural Regener Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-18101","article-title":"DNA damage response in proliferating M\u00fcller glia in the mammalian retina","volume":"57","author":"Nomura-Komoike","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.169","article-title":"How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression","volume":"25","author":"Aubrey","year":"2018","journal-title":"Cell Death Differ"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/science.1108297","article-title":"ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex","volume":"308","author":"Lee","year":"2005","journal-title":"Science"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2023.119654","article-title":"Disordered regions mediate the interaction of p53 and MRE11","volume":"1871","author":"Usluer","year":"2024","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01990-14","article-title":"Insight into the mechanism of inhibition of adeno-associated virus by the Mre11\/Rad50\/Nbs1 complex","volume":"89","author":"Lentz","year":"2015","journal-title":"J Virol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01523-07","article-title":"The Mre11\/Rad50\/Nbs1 complex limits adeno-associated virus transduction and replication","volume":"81","author":"Schwartz","year":"2007","journal-title":"J Virol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.omtm.2023.01.001","article-title":"Erratum: Enhancement of adeno-associated virus-mediated gene therapy using hydroxychloroquine in murine and human tissues","volume":"28","author":"Chandler","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.omtm.2023.01.001","article-title":"Enhancement of adeno-associated virus-mediated gene therapy using hydroxychloroquine in murine and human tissues","volume":"14","author":"Chandler","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.999021","article-title":"Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood","volume":"13","author":"Smith","year":"2022","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01990-07","article-title":"Complement is an essential component of the immune response to adeno-associated virus vectors","volume":"82","author":"Zaiss","year":"2008","journal-title":"J Virol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00337","article-title":"Complement in thrombotic microangiopathies: Unraveling Ariadne's thread into the labyrinth of complement therapeutics","volume":"10","author":"Gavriilaki","year":"2019","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv"},{"key":"B56","article-title":"C3 Complement Inhibitor Limits Transaminitis and Immune Response Following Liver Targeted Adeno-Associated Virus (AAV) Gene Transfer (GT) in Non-Human Primates (NHPs)","volume":"32","author":"Kropf","year":"2024","journal-title":"Mol Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01007","article-title":"The challenges and promise of complement therapeutics for ocular diseases","volume":"10","author":"Park","year":"2019","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103757","article-title":"Therapeutic targeting of the complement system in ocular disease","volume":"28","author":"Rathi","year":"2023","journal-title":"Drug Discov Today"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100453","article-title":"Aqueous macrophages contribute to conserved CCL2 and CXCL10 gradients in uveitis","volume":"4","author":"Lin","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20080421","article-title":"Ly6c+ \"inflammatory monocytes\" are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis","volume":"205","author":"Getts","year":"2008","journal-title":"J Exp Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.50.1.224","article-title":"Effects of intravenous methylprednisolone therapy on leukocyte and soluble adhesion molecule expression in MS","volume":"50","author":"Droogan","year":"1998","journal-title":"Neurology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/bf01062461","article-title":"Pharmacoimmunodynamics of methylprednisolone: Trafficking of helper T lymphocytes","volume":"20","author":"Fisher","year":"1992","journal-title":"J Pharmacokinet Biopharm"},{"key":"B63","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.exer.2015.06.017","article-title":"ICAM-1 and VCAM-1 are differentially expressed on blood-retinal barrier cells during experimental autoimmune uveitis","volume":"137","author":"Dewispelaere","year":"2015","journal-title":"Exp Eye Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183837","article-title":"Mouse models of human ocular disease for translational research","volume":"12","author":"Krebs","year":"2017","journal-title":"PloS One"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.65.1.13","article-title":"Comparative analysis of molecular landscape in mouse models and patients reveals conserved inflammation pathways in age-related macular degeneration","volume":"65","author":"Liu","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867015","article-title":"A comprehensive atlas of immunological differences between humans, mice, and non-human primates","volume":"13","author":"Bjornson-Hooper","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1799327\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:54:06Z","timestamp":1776837246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1799327\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2026.1799327"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1799327","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1799327"}}